Pure Global
NCT06150924

Efficacy and Safety of Lorundrostat Alone, and in Combination With Dapagliflozin in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria

A Phase 2 Study to Evaluate the Efficacy and Safety of Lorundrostat Alone, and Lorundrostat in Combination With Dapagliflozin, in Adults With Hypertension and Chronic Kidney Disease With Albuminuria
Mineralys Therapeutics Inc.·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chronic Kidney Disease
Drug/Device/Intervention
Part A - Lorundrostat QD + Dapaglifozin QD
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Mineralys Therapeutics Inc.
Timeline & enrollment
Phase
Phase 2
Start date
Dec 01, 2023
End date
Jan 01, 2025
Enrollment
80 participants
Primary outcome

Part A: Change from baseline in automated office blood pressure (AOBP) SBP at Week 8,Part B: Incidence and severity of AEs

Summary

This is a 2-part study evaluating the efficacy and safety of lorundrostat (an aldosterone
 synthase inhibitor [ASI]) for the treatment of hypertension in subjects with CKD and
 albuminuria while receiving stable treatment with an angiotensin converting enzyme inhibitor
 (ACEi) or an angiotensin receptor blocker (ARB) either in combination with dapagliflozin, or
 alone.

ICD-10 classifications
Chronic kidney diseaseChronic kidney disease, unspecifiedChronic kidney disease, stage 1Chronic kidney disease, stage 4Chronic kidney disease, stage 2
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06150924
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06150924 through Pure Global AI's free database. This Phase 2 trial is sponsored by Mineralys Therapeutics Inc. and is currently Not yet recruiting. The study focuses on Chronic Kidney Disease. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.